

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the unaudited consolidated financial statements, the Group expects to record during the six months ended 30 June 2023 (the “**Reporting Period**”):

- (i) Revenue ranging from approximately RMB290 million to RMB310 million, representing an increase of approximately 41% to 51% as compared to the corresponding period of the last year;
- (ii) Profit from operations ranging from approximately RMB75 million to RMB90 million, representing an increase of approximately 452% to 563% as compared to the corresponding period of the last year;
- (iii) Net profit ranging from approximately RMB45 million to RMB60 million, turning losses into profits as compared to the corresponding period of the last year.

Based on currently available information, the Board considers that the aforementioned expected increase in the revenue and profitability of the Group is principally attributable to the following reasons:

- (i) The Group’s market-share leading products (including Tubridge® Flow-diverting Stent, etc.) continued to increase the market penetration, further consolidated the competitive advantages and maintained positive growth trends;

- (ii) The continued tendering and admission of several new products launched by the Group in recent years (including NUMEN[®] Coil Embolization System, Bridge[®] Rapamycin Target Eluting Vertebral Artery Stent System and U-track[®] Intracranial Support Catheter System) into hospitals has contributed to the exploration of blank markets;
- (iii) The Group's newly approved products in 2022 (including Neurohawk[®] Stent Thrombectomy Device and Diveer[®] Intracranial Balloon Dilatation Catheter) accelerated the market development and contributed to the growth of the Group's revenue.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the unaudited interim results of the Group for the six months ended 30 June 2023 (the “**2023 Interim Results**”). The information contained in this announcement is only a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Shareholders and potential investors of the Company are advised to read the Company's 2023 Interim Results carefully, which is expected to be published by the end of August 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort NeuroTech Limited
Mr. Peng Bo
Chairman

Hong Kong, 16 July 2023

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.